in the following description , for the purposes of explanations , numerous specific details are set forth in order to provide a thorough understanding of the present invention . it will be apparent , however , to one of ordinary skill in the art that the present invention may be practiced without these specific details . the present invention is directed towards a nutritional composition for promoting weight loss in an individual by acting to concomitantly increase the satiety of an individual by increasing cck and glp - 1 activity , and decreasing the absorption of carbohydrates by inhibiting the activity of a - glucosidase . it is herein understood that the activity of signaling molecules such as cck and glp - 1 are the result of the activity of mature signaling molecules in concert with the corresponding receptors . as such , the activity of such signaling molecules may be modulated by affecting any number of mechanisms including but not limited to : signaling molecules and receptor synthesis , secretion , modification , transport , and recognition and binding . it is also understood that the activity of enzymes such as a - glucosidase are the result of the activity of the mature protein . as such , the activity of such enzymes may be modulated by affecting any number of mechanisms including but not limited to : enzyme transcription , translation , post - translational modification , secretion , transport and cofactor binding . it is further understood that the body weight of an individual is determined by the effect of both caloric intake from ingested absorbed food and caloric expenditure from basal metabolism and activity . as such reducing the calories absorbed by reducing food intake due to feelings of ‘ fullness ’ due to increased satiety and reduced carbohydrate absorption will have the net effect of promoting weight loss . as used herein , the term ‘ nutritional composition ’ includes dietary supplements , diet supplements , nutritional supplements , supplemental compositions and supplemental dietary compositions or those similarly envisioned and termed compositions not belonging to the conventional definition of pharmaceutical interventions as is known in the art . furthermore , ‘ nutritional compositions ’ as disclosed herein belong to category of compositions having at least one physiological function when administered to a mammal by conventional routes of administration . alternatively , formulations and nutritional compositions belonging to the present invention may be considered to be nutraceuticals . as used herein , the term ‘ nutraceutical ’ is recognized and used in the art to describe a specific chemical compound or combination of compounds found in , organic matter for example , which may prevent , ameliorate or otherwise confer benefits against an undesirable condition . as is known in the art , the term ‘ nutraceutical ’ is used to refer any substance that is a food , a part of food , or an extract of food which is suitable for consumption by an individual and providing physiological benefit which may be medical or health - related . furthermore , the term has been used to refer to a product isolated , extracted or purified from foods or naturally - derived material suitable for consumption by an individual and usually sold in medicinal forms , such as caplets , tablet , capsules , soft - gel ™ caplets , gel - caps and the like , not associated with food . extracts suitable for use in the present invention may be produced by extraction methods as are known and accepted in the art such as alcoholic extraction , aqueous extractions , carbon dioxide extractions , for example . mulberry ( morus alba ) is an edible plant used in chinese medicine rich in flavonoids with antioxidant activity ( doi k , kojima t , makino m , kimura y , fujimoto y . studies on the constituents of the leaves of morus alba l . chem pharm bull ( tokyo ). 2001 february ; 49 ( 2 ): 151 - 3 ). mulberry leaves have been shown to result in weight loss and reduced postprandial glucose increase , indicative of reduced carbohydrate absorption ( enkhmaa b , shiwaku k , katsube t , kitajima k , anuurad e , yamasaki m , yamane y . mulberry ( morus alba l .) leaves and their major flavonol quercetin 3 -( 6 - malonylglucoside ) attenuate atherosclerotic lesion development in ldl receptor - deficient mice . j . nutr . 2005 april ; 135 ( 4 ): 729 - 34 ). furthermore , a tea extract containing mulberry has been shown to reduce carbohydrate absorption in humans ( zhong l , furne j k , levitt m d . an extract of black , green , and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers . am j clin nutr . 2006 september ; 84 ( 3 ): 551 - 5 ) which is thought to be due to constituents of mulberry that inhibit a - glucosidase . it is herein understood by the inventors that the incorporation of an extract of mulberry in a nutritional composition for promoting weight loss will effectively inhibit the absorption of carbohydrates from ingested food by inhibiting α - glucosidase . an embodiment of the present invention comprises between from about 0 . 01 g to about 2 . 0 g of an extract of mulberry leaves per serving of the supplemental composition . in an embodiment , the supplemental composition comprises from about 0 . 05 g to about 1 . 5 g of an extract of mulberry leaves per serving of supplement composition . in a further embodiment , the supplemental composition comprises about 1 . 2 g of an extract of mulberry leaves per serving of supplemental composition . pinolenic acid is a triple - unsaturated fatty acid which is a positional isomer of the more common gamma - linolenic acid which is found exclusively in pine nut oil . at a meeting of the american chemical society , it was reported that in a randomized , double - blind placebo - controlled trial , pine nut fatty acids increase circulating levels of cck and glp - 1 concomitant with decreased appetite and increased satiety ( causey j l . korean pine nut fatty acids induce satiety - producing hormone release in overweight human volunteers . paper presented at : american chemical society national meeting & amp ; exposition ; mar . 26 - 30 , 2006 ; atlanta , ga .). it is herein understood by the inventors that the incorporation of a source of pinolenic in a nutritional composition for promoting weight loss will effectively decrease appetite and increase satiety by increasing the circulating levels of ckk and glp - 1 . an embodiment of the present invention comprises between from about 0 . 001 mg to about 100 mg of pinolenic acid per serving of the supplemental composition . in an embodiment , the supplemental composition comprises from about 0 . 01 mg to about 10 . 0 mg of pinolenic acid per serving of supplement composition . in a further embodiment , the supplemental composition comprises about 1 . 0 mg of pinolenic acid per serving of supplemental composition . salacia oblonga extract is known to be an α - glucosidase inhibitor . glucosidase inhibitors decrease the absorption of carbohydrates from the intestine , resulting in a slower and lower rise in blood sugar following the consumption of a meal . carbohydrates must be broken down before they can be absorbed from food into simple sugars , such as glucose , by enzymes in the intestine . α - glucosidase is one of the enzymes involved in breaking down carbohydrates . through the inhibition of this enzyme , carbohydrates are not broken down as efficiently and glucose absorption is thus delayed or at least partially prevented . heacock et al ., 2005 . showed that compared to controls in non - diabetic adults a dose of 1000 mg of salacia oblonga reduced serum glucose and insulin levels by 29 % ( p = 0 . 01 ) 120 minutes following the ingestion of a study beverage consisting of 14 g of fat , 82 g of carbohydrates , and 20 g of protein ( heacock p m , hertzier s r , williams j a , wolf b w . effects of a medical food containing an herbal alpha - glucosidase inhibitor on postprandial glycemia and insulinemia in healthy adults . jam diet assoc . 2005 january ; 105 ( 1 ): 65 - 71 ). in a separate study , following the administration of a beverage the same as outlined above , it was determined that at 120 minutes following the simultaneous administration of 1000 mg of an extract of salacia oblonga , plasma glucose was reduced relative to controls by 27 % ( p = 0 . 035 ) for the area under the curve measurements . the same study also determined , under the above conditions , that at times of 120 and 180 minutes post - administration of the study beverage and salacia oblonga extract , there was a 35 % and 36 % ( p & lt ; 0 . 001 ) reduction in serum insulin levels compared to control ( collene a l , hertzler s r , williams j a , wolf b w . effects of a nutritional supplement containing salacia oblonga extract and insulinogenic amino acids on postprandial glycemia , insulinemia , and breath hydrogen responses in healthy adults . nutrition . 2005 july - august ; 21 ( 7 - 8 ): 848 - 54 ). these results suggest that the salacia oblonga extract is effective in decreasing glycemia through its activity as an α - glucosidase inhibitor . it is herein understood by the inventors that the incorporation of an extract of salacia oblonga in a nutritional composition for promoting weight loss will effectively inhibit the absorption of carbohydrates from ingested food by acting as an α - glucosidase inhibitor . an embodiment of the present invention comprises between from about 0 . 001 g to about 0 . 1 g of an extract of salacia oblonga per serving of the supplemental composition . in an embodiment , the supplemental composition comprises from about 0 . 005 g to about 0 . 05 g of an extract of salacia oblonga per serving of supplement composition . in a further embodiment , the supplemental composition comprises about 0 . 01 g of an extract of salacia oblonga per serving of supplemental composition . it is herein understood by the inventors that the components of the present invention , when administered to an individual , will promote weight loss . said weight loss will be the result of the concomitant action of increased sensations of satiety and decreased absorption of carbohydrates . additional embodiments of the present invention may also include portions of the composition as fine - milled ingredients . u . s . non - provisional patent application ser . no . 11 / 709 , 526 entitled “ method for increasing the rate and consistency of bioavailability of supplemental dietary ingredients ” filed feb . 21 , 2007 , which is herein fully incorporated by reference , discloses a method of increasing the rate of bioavailability following oral administration of components comprising supplemental dietary compositions by the process of particle - milling . for the purposes of the present invention , the terms micronization , milling , particle - milling , and fine - milling are used interchangeably , wherein they refer to a technology , process and end - products involved in or leading to a narrowing of particle size range and a concomitant reduction in the average particle size . for the purposes of the present invention , acceptable milled - particle sizes are in the range of from about 1 nanometer to about 500 microns . further to improving bioavailability , it is understood by the inventors that increased solubility resulting from fine - milling will lead to improvements in characteristics in which solubility and reduced particle size likely play a role . furthermore , additional embodiments of the present invention may be incorporated into specific controlled - release solid dosage forms . u . s . non - provisional patent application ser . no . 11 / 709 , 525 entitled “ method for a supplemental dietary composition having a multi - phase dissolution profile ” filed feb . 21 , 2007 , which is herein fully incorporated by reference , discloses a method of achieving a solid oral dosage form with multiple dissolution characteristics for the release of active ingredients . conventional oral dosage formulations are bound by the rate of dissolution of the unprocessed substance , thereby limiting the rate of bioavailability of the substance upon oral administration . this is particularly problematic for poorly - soluble compounds which have an inherently low rate of dissolution in that they may be excreted prior to first - pass . it is herein understood that , due to the relationship between solubility and dissolution , the amount of a substance in solution at any given time is dependent upon both dissolution and solubility . furthermore , it is understood by way of extension that increasing the rate of dissolution of a given substance acts to reduce the time to dissolution of a given solute or substance in a given solvent . however , the absolute solubility of said solute does not increase with infinite time . thus , increasing the rate of dissolution of a substance will increase the amount of said substance in solution at earlier points in time , thus increasing the rate of bioavailability of said substance at earlier times upon oral administration . the increase in the rate of bioavailability will allow better and quicker compound transfer to the systemic parts of the body . micronization is a technique which has been used as a method of sizing solid compounds to fine powders . following a micronization process , compounds and more specifically poorly soluble compounds are transformed into fine powders which can then be transformed into suitable , stable and patient - compliant dosage forms . these forms , for the purposes of the present invention are derived for oral administration . micronization techniques offer an advantage over larger forms of compounds and poorly soluble compounds — following micronization , compounds have higher surface area to volume ratio . this provides for , as compared to physically coarse compounds , an ultrafine micronized powder that has a significantly increased total surface area . mathematically , cross - sectional surface area increases with the square of the radius , while volume increases with the cube of the radius . therefore , as a particle becomes smaller , the volume of the particle decreases at a faster rate than the surface area leading to an increase in the ratio of surface area to volume . by way of theoretical calculations , decreasing the size of a particle can increase its rate of dissolution via increasing the surface area to volume ratio . in the case of solubility , this increase in relative surface area allows for greater interaction with solvent . additional embodiments of the present invention may employ a multi - phasic dissolution profile to provide a time - release mechanism . according to various embodiments of the present invention , the nutritional supplement may be consumed in any form . for instance , the dosage form of the nutritional supplement may be provided as , e . g ., a powder beverage mix , a liquid beverage , a ready - to - eat bar or drink product , a capsule , a liquid capsule , a tablet , a caplet , or as a dietary gel . the preferred dosage forms of the present invention are as a caplet or as a liquid capsule . furthermore , the dosage form of the nutritional supplement may be provided in accordance with customary processing techniques for herbal and nutritional supplements in any of the forms mentioned above . additionally , the nutritional supplement set forth in the example embodiment herein may contain any appropriate number and type of excipients , as is well known in the art . the present nutritional composition or those similarly envisioned by one of skill in the art may be utilized in methods to promote weight loss in a formulation designed to be consumed on a daily basis . although the following examples illustrate the practice of the present invention in four of its embodiments , the examples should not be construed as limiting the scope of the invention . other embodiments will be apparent to one of skill in the art from consideration of the specifications and example . a nutritional supplement is provided in two servings per day as caplets . a single serving of the nutritional composition comprises from about 0 . 05 g to about 1 . 5 g of an extract of mulberry leaves , from about 0 . 01 mg to about 10 . 0 mg of pinolenic acid and from about 0 . 005 g to about 0 . 05 g of an extract of salacia oblonga . directions : as a diet supplement , 2 caplets are administered with an 8 oz . glass of water two ( 2 ) times daily approximately 30 to 60 minutes before meals . a nutritional supplement is provided in two servings per day as caplets . a single serving of the nutritional composition comprises about 1 . 2 g of an extract of mulberry leaves , about 1 . 0 mg of pinolenic acid and about 0 . 01 g of an extract of salacia oblonga . directions : as a diet supplement , 2 caplets are administered with an 8 oz . glass of water two ( 2 ) times daily approximately 30 to 60 minutes before meals . in the foregoing specification , the invention has been described with a specific embodiment thereof ; however , it will be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention .
a nutritional composition for promoting weight loss by jointly and simultaneously suppressing appetite , increasing satiation , decreasing the metabolic breakdown of carbohydrates and decreasing the absorption of carbohydrates in an individual comprising , effective amounts of an extract of mulberry leaf , pinolenic acid and an extract of salacia oblonga is provided . both a composition and a method are provided by the present disclosure .